The three RUNX family members are lineage specific master regulators, which also have
important, context-dependent roles in carcinogenesis as either tumor suppressors or …

Skeletal lesions are a frequent complication of breast and prostate cancer and a hallmark of
multiple myeloma. Endocrine and paracrine factors modulate various aspects of bone …

Introduction In contrast to its role in breast cancer (BCa) initiation, estrogen signaling has a
protective effect in later stages, where estrogen receptor (ER) α loss associates with …

RUNX1 encodes a RUNX family transcription factor (TF) and was recently identified as a
novel mutated gene in human luminal breast cancers. We found that Runx1 is expressed in …

Recent high-throughput studies revealed recurrent RUNX1 mutations in breast cancer,
specifically in oestrogen receptor-positive (ER+) tumours. However, mechanisms underlying …

Runx2 is best known as an essential factor in osteoblast differentiation and bone
development but, like many other transcription factors involved in development, is known to …

Highlights•Endocrine treatment resistance in estrogen receptor positive breast
cancer.•Technological advancements for the discovery of biomarkers of endocrine …

Although the deregulation of lysine methyltransferase (su (var)-3–9, enhancer-of-zeste,
trithorax) domain-containing protein 7/9 (SET7/9) has been identified in a variety of cancers …

Runx1 is a transcription factor essential for definitive hematopoiesis, and genetic
abnormalities in Runx1 cause leukemia. Runx1 is functionally promiscuous and acts as …

Breast cancer is one of the most prevalent forms of cancer in women. The currently available
treatment for breast cancer is mostly curative except when it becomes metastatic. One of the …